Adagio Therapeutics, Inc. (ADGI)
| Market Cap | 5.58B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -65.32M |
| Shares Out | 108.52M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,804,930 |
| Open | 56.02 |
| Previous Close | 56.08 |
| Day's Range | 50.28 - 59.50 |
| 52-Week Range | 20.50 - 59.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About ADGI
Adagio Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. Our lead product candidate, ADG20, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent. We have completed enrollment in our first-in-human Phase 1 clinical trial of ADG20. We are also conducting two separate Phase 2/3 clinical trials: ...
News
Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial
Adagio Therapeutics Inc (NASDAQ: ADGI) announced that the independent data monitoring committee (IDMC) has recommended expanding the ADG20 EVADE Phase 2/3 trial for COVID-19. The IDMC has supported the ...
3 Biotech Stocks That Soared to New Heights Last Week
Find out what these industry favorites are doing to impress investors.
Adagio Therapeutics Announces Pricing of Initial Public Offering
WALTHAM, Mass.--(BUSINESS WIRE)--Adagio Therapeutics Announces Pricing of Initial Public Offering
COVID-19 antibody biotech Adagio Therapeutics files for a $100 million IPO
Adagio Therapeutics, a Phase 1 biotech developing antibody therapies COVID-19 and other infectious diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Adagio Therapeutics IPO Registration Document (S-1)
Adagio Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.